Résumé
L’insuffisance médullaire est assez fréquente dans le cancer du sein métastatique, soit par envahissement de la moelle par des cellules métastatiques, soit par épuisement après traitements antérieurs par diverses lignes de chimiothérapie et par radiothérapie, que ce soit de la tumeur primitive ou de métastases osseuses. Cette insuffisance médullaire doit être prise en compte dans les décisions thérapeutiques et le rapport risque/bénéfice des chimiothérapies et de leurs traitements de support doit être consciencieusement pesé.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
Références
NCCN (2009) Practice guidelines in oncology myeloid growth factors v1. www.nccn.org
Kuderer NM, Dale DC, Crawford J et al. (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106: 2258–2266
Zielinski CC, Awada A, Cameron DA et al. (2008) The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. Eur J Cancer 44: 353–365
Smith TJ, Khatcheressian J, Lyman GH et al. (2006) 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: Evidence-Based Clinical Practice Guideline. J Clin Oncol 24: 3187–3205
Aapro MS, Cameron DA, Pettengell R et al. (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42: 2433–2453
Vogel CL, Wojtukiewicz MZ, Carroll RR et al. (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23: 1178–1184
Von Minckwitz G, Schwenkglenks M, Skacel T et al. (2009) Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutroaenia management: results from an integrated analysis. Eur J Cancer 45: 608–617
Papaldo P, Lopez M, Marolla P et al. (2005) Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 23: 6908–6918
Liutkauskiene S, Sveikata A, Juozaityte E et al. (2009) Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin. Medicina (Kaunas) 45: 600–606
Hershman D, Neugut AI, Jacobson JS et al. (2007) Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99: 196–205
Briasoulis E, Andreopoulou E, Tolis CF et al. (2001) G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer 91: 909–917
Pentheroudakis G, Malamou-Mitsi V, Briasoulis E et al. (2004) The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocytecolony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy. Cancer 101: 1767–1775
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag France
About this chapter
Cite this chapter
Mayeur, D. (2010). Poursuite des traitements spécifiques et prise en charge des symptômes en situation métastatique : quelle prise de risque en cas de neutropénie ?. In: Cancer du sein en situation métastatique. Springer, Paris. https://doi.org/10.1007/978-2-8178-0076-9_27
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0076-9_27
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0075-2
Online ISBN: 978-2-8178-0076-9